Brenner Martin 4

What Happened
Martin Brenner, iBio’s Chief Executive Officer and Chief Scientific Officer (and director), received an award of options covering 479,000 shares of iBio common stock on January 28, 2026. The grant is reported as a derivative acquisition with an acquisition price listed as $0.00 and a reported dollar amount of $0 at grant. This is an equity compensation award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-01-28; Form 4 filed 2026-01-30 (appears timely).
• Award: options covering 479,000 shares of common stock; acquisition price shown as $0.00 (derivative).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnote (vesting): 25% of the shares underlying the options vest on the one-year anniversary of the grant; the remainder vests in equal quarterly installments over the following 36 months, subject to continued employment.
• No indication in the filing that any shares were immediately sold or that a 10b5-1 plan or tax-withholding disposition was used.

Context
This was a standard executive equity grant rather than a purchase or sale. Because these are options (derivative awards) that vest over time, they do not represent immediate share ownership or a liquidity event. Executive grants are common for retention and incentive; the filing is informational and should not be taken as a direct buy/sell signal.